Inflammation and Immunology UK Areas of Interest

Inflamation and immunology areas of interest

Healthcare organisations are invited to submit grant requests to our inflammation and immunology business unit for the support of independent medical and/or scientific initiatives, that are aligned to Pfizer's medical and/or scientific strategies.

 

The Inflammation and Immunology Unit at Pfizer UK will consider high-quality submissions for independent medical education programs, independent general research, and quality improvement initiatives in the following areas:

Rheumatology: Adult and paediatric populations with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Axial Spondyloarthritis (axSpA), Juvenile Idiopatic Arthritis (JIA), Systemic Lupus Erythematosus (SLE) and Inflammatory Myopathies

Independent Medical Grant areas to be considered for Pfizer support include:

  • Evidence generation for chronic inflammatory arthritis, lupus, and inflammatory myopathies, particularly the UK pathway based on Real World Data (RWD)
  • Health services research for inflammatory arthritis, lupus, and inflammatory myopathies in the NHS setting, including improvement in patient pathways
  • Projects exploring new models of care, such as, digital patient initiatives that improve clinician-patient communication and patient treatment experience, patient safety and/or adherence to therapy.
  • Basic science research investigating mechanisms relating to Janus Kinase (JAK) pathways and inflammation
  • Audits or observational studies of management and/or outcomes of chronic inflammatory arthritis patients with co-morbidities (specific populations)
  • Studies investigating treatment adherence to oral dosing and/or patient preference in chronic inflammatory arthritis in adult or paediatric populations
  • Research exploring factors associated with failure to achieve therapeutic target
  • Stratified Medicine initiatives to better improve patient care
  • Projects optimising medical education, diagnostics, therapy and delivery of care, which may include the development of novel artificial intelligence and telemedicine approaches
  • Qualitative research in paediatric juvenile idiopathic arthritis
  • Research exploring impact of chronic inflammatory arthritis, lupus, and inflammatory myopathies on work ability and other social outcomes.

 

Dermatology: Adult and paediatric populations with Alopecia Areata (AA), Atopic Dermatitis (AD), Psoriasis (PsO) and Vitiligo

Independent Medical Grant areas to be considered for Pfizer support include:

  • Evidence generation for AA, AD, PsO, and vitiligo, specifically to the UK patient pathway based on Real World Data (RWD)
  • Health services research for AA, AD, PsO, and vitiligo in the NHS setting, including improvement in patient pathways
  • Projects exploring innovative models of care, such as digital patient initiatives, that improve clinician-patient communication and patient treatment experience, patient safety and/or adherence to therapy
  • Fundamental research focused on mechanisms related to Janus Kinase (JAK) pathways in skin diseases
  • Epidemiology of target skin diseases at the primary and secondary care levels in the UK
  • Economic burden of the target skin diseases to the NHS
  • Projects optimising healthcare delivery, quality improvement and patient care in relation to AD, AA, PsO and vitiligo
  • Research developing individualised treatment strategies in AD
  • Projects optimising medical education, diagnostics, therapy and delivery of care, which may include the development of novel artificial intelligence and telemedicine approaches
  • Research exploring Health-Related Quality of Life burden and mental health associations relating to AA, AD, PsO and vitiligo.

 

Gastroenterology: Adult and paediatric populations with Ulcerative Colitis (UC) and Crohn’s Disease (CD)

Independent Medical Grant areas to be considered for Pfizer support include:

  • Understanding disease management in UC and new measures of efficacy (e.g. treat to target, development of new tools, measures of efficacy, biomarkers)
  • Understanding treatment and efficacy of JAK inhibitor in severe, acute flare in UC
  • Research developing personalised medicine approaches in UK UC patients
  • Real world data generation investigating the effect of JAK inhibition in adult UC, specific to UK patient pathways
  • Projects optimising medical education, diagnostics, therapy and delivery of care in UC and CD, including the development of novel artificial intelligence and telemedicine approaches
  • Support for basic science research - investigating mechanisms relating to JAK pathways and inflammation in UC



For all independent medical grants, the grant recipient is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Pfizer must not be involved in any aspect of project development, nor its conduct or monitoring.

To discuss your potential independent medical grant application for any of the above areas, please phone 01304 616161 and ask to speak to a member of the inflammation and immunology medical affairs team.

 

PP-PFE-GBR-4349 / February 2022